Insights from Three Pan-European Multicentre Studies on Invasive Candida Infections and Outlook to ECMM Candida IV.

Humans Candidiasis, Invasive / drug therapy Antifungal Agents / therapeutic use Candida / drug effects Drug Resistance, Fungal Europe / epidemiology Candidemia / drug therapy Multicenter Studies as Topic
Candida Candidemia European Confederation of Medical Mycology (ECMM)

Journal

Mycopathologia
ISSN: 1573-0832
Titre abrégé: Mycopathologia
Pays: Netherlands
ID NLM: 7505689

Informations de publication

Date de publication:
01 Aug 2024
Historique:
received: 11 04 2024
accepted: 20 06 2024
medline: 1 8 2024
pubmed: 1 8 2024
entrez: 1 8 2024
Statut: epublish

Résumé

Invasive candidiasis and candidemia remain a significant public health concern. The European Confederation of Medical Mycology (ECMM) conducted three pan-European multicentre studies from 1997 to 2022 to investigate various aspects of invasive Candida infections. These studies revealed shifting trends in Candida species distribution, with an increase of non-albicans Candida species as causative pathogens, increasing rates of antifungal resistance, and persistently high mortality rates. Despite advancements in antifungal treatment, the persistently high mortality rate and increasing drug resistance, as well as limited drug access in low-income countries, underscore the need for continued research and development in the treatment of Candida infections. This review aims to summarize the findings of the three completed ECMM Candida studies and emphasize the importance of continued research efforts. Additionally, it introduces the upcoming ECMM Candida IV study, which will focus on assessing candidemia caused by non-albicans Candida species, including Candida auris, investigating antifungal resistance and tolerance, and evaluating novel treatment modalities on a global scale.

Identifiants

DOI: 10.1007/s11046-024-00871-0 PMID: 39088098
pubmed: 39088098
doi: 10.1007/s11046-024-00871-0
pii: 10.1007/s11046-024-00871-0
doi:

Substances chimiques

Antifungal Agents 0

Types de publication

Journal Article Review

Langues

eng

Sous-ensembles de citation

IM

Pagination

70

Informations de copyright

© 2024. The Author(s).

Références

Strollo S, et al. Epidemiology of hospitalizations associated with invasive candidiasis, United States, 2002–2012(1). Emerg Infect Dis. 2016;23(1):7–13.
pubmed: 27983497 doi: 10.3201/eid2301.161198
Alvarez-Moreno CA, et al. The mortality attributable to Candidemia in C. auris is higher than that in other Candida species: myth or reality? J Fungi (Basel). 2023;9(4):430.
pubmed: 37108885 doi: 10.3390/jof9040430
Pappas PG, et al. Invasive candidiasis. Nat Rev Dis Primers. 2018;4:18026.
pubmed: 29749387 doi: 10.1038/nrdp.2018.26
Egger M, et al. Let’s talk about sex characteristics-As a risk factor for invasive fungal diseases. Mycoses. 2022;65(6):599–612.
pubmed: 35484713 doi: 10.1111/myc.13449
Kayaaslan B, et al. Characteristics of candidemia in COVID-19 patients; increased incidence, earlier occurrence and higher mortality rates compared to non-COVID-19 patients. Mycoses. 2021;64(9):1083–91.
pubmed: 34085319 pmcid: 8242769 doi: 10.1111/myc.13332
Bongomin F, et al. Global and multi-national prevalence of fungal diseases-estimate precision. J Fungi (Basel). 2017;3(4):57.
pubmed: 29371573 doi: 10.3390/jof3040057
Denning DW. Global incidence and mortality of severe fungal disease. Lancet Infect Dis. 2024;24:268.
doi: 10.1016/S1473-3099(24)00102-6
Barantsevich N, Barantsevich E. Diagnosis and treatment of invasive candidiasis. Antibiotics (Basel). 2022;11(6):718.
pubmed: 35740125 doi: 10.3390/antibiotics11060718
Bassetti M, et al. Incidence and outcome of invasive candidiasis in intensive care units (ICUs) in Europe: results of the EUCANDICU project. Crit Care. 2019;23(1):219.
pubmed: 31200780 pmcid: 6567430 doi: 10.1186/s13054-019-2497-3
de Hoog S, et al. A conceptual framework for nomenclatural stability and validity of medically important fungi: a proposed global consensus guideline for fungal name changes supported by ABP, ASM, CLSI, ECMM, ESCMID-EFISG, EUCAST-AFST, FDLC, IDSA, ISHAM, MMSA, and MSGERC. J Clin Microbiol. 2023;25:e0087323.
doi: 10.1128/jcm.00873-23
Spampinato C, Leonardi D. Candida infections, causes, targets, and resistance mechanisms: traditional and alternative antifungal agents. Biomed Res Int. 2013;2013: 204237.
pubmed: 23878798 pmcid: 3708393 doi: 10.1155/2013/204237
Seidel D, et al. Impact of climate change and natural disasters on fungal infections. Lancet Microbe. 2024;879:56–8.
Satoh K, et al. Candida auris sp. nov., a novel ascomycetous yeast isolated from the external ear canal of an inpatient in a Japanese hospital. Microbiol Immunol. 2009;53(1):41–4.
pubmed: 19161556 doi: 10.1111/j.1348-0421.2008.00083.x
Casadevall A, Kontoyiannis DP, Robert V. On the emergence of Candida auris: climate change, azoles, swamps, and birds. MBio. 2019;10(4):785.
doi: 10.1128/mBio.01397-19
Fisher MC, Denning DW. The WHO fungal priority pathogens list as a game-changer. Nat Rev Microbiol. 2023;21(4):211–2.
pubmed: 36747091 pmcid: 9901396 doi: 10.1038/s41579-023-00861-x
Lyman M, et al. Worsening spread of Candida auris in the United States, 2019 to 2021. Ann Intern Med. 2023;176(4):489–95.
pubmed: 36940442 doi: 10.7326/M22-3469
Chowdhary A, Jain K, Chauhan N. Candida auris genetics and emergence. Annu Rev Microbiol. 2023;77:583–602.
pubmed: 37406342 doi: 10.1146/annurev-micro-032521-015858
Lass-Flörl C, et al. Invasive candidiasis. Nat Rev Dis Primers. 2024;10(1):20.
pubmed: 38514673 doi: 10.1038/s41572-024-00503-3
Tortorano AM, et al. Epidemiology of candidaemia in Europe: results of 28-month European Confederation of Medical Mycology (ECMM) hospital-based surveillance study. Eur J Clin Microbiol Infect Dis. 2004;23(4):317–22.
pubmed: 15029512 doi: 10.1007/s10096-004-1103-y
Klingspor L, et al. Invasive Candida infections in surgical patients in intensive care units: a prospective, multicentre survey initiated by the European Confederation of Medical Mycology (ECMM) (2006–2008). Clin Microbiol Infect. 2015;21(1):87.e1-87.e10.
pubmed: 25636940 doi: 10.1016/j.cmi.2014.08.011
Hoenigl M, et al. Guideline adherence and survival of patients with candidaemia in Europe: results from the ECMM Candida III multinational European observational cohort study. Lancet Infect Dis. 2023;23(6):751–61.
pubmed: 37254300 doi: 10.1016/S1473-3099(22)00872-6
Mellinghoff SC, et al. EQUAL Candida Score: An ECMM score derived from current guidelines to measure QUAlity of Clinical Candidaemia Management. Mycoses. 2018;61(5):326–30.
pubmed: 29325218 doi: 10.1111/myc.12746
El Zakhem A, et al. The utility of EQUAL candida score in predicting mortality in patients with candidemia. J Fungi (Basel). 2022;8(3):238.
pubmed: 35330240 doi: 10.3390/jof8030238
Leepattarakit T, et al. EQUAL Candida score, an effective tool for predicting the outcomes of Candida tropicalis candidaemia: a retrospective cohort study. Mycoses. 2022;65(4):473–80.
pubmed: 35138673 doi: 10.1111/myc.13429
De Pauw B, et al. Revised definitions of invasive fungal disease from the European Organization for Research and Treatment of Cancer/Invasive Fungal Infections Cooperative Group and the National Institute of Allergy and Infectious Diseases Mycoses Study Group (EORTC/MSG) Consensus Group. Clin Infect Dis. 2008;46(12):1813–21.
pubmed: 18462102 doi: 10.1086/588660
Cuenca-Estrella M, et al. ESCMID* guideline for the diagnosis and management of Candida diseases 2012: diagnostic procedures. Clin Microbiol Infect. 2012;18(Suppl 7):9–18.
pubmed: 23137134 doi: 10.1111/1469-0691.12038
Salmanton-García J, et al. EPICOVIDEHA: a ready to use platform for epidemiological studies in hematological patients with COVID-19. Hemasphere. 2021;5(7): e612.
pubmed: 34235404 pmcid: 8232068 doi: 10.1097/HS9.0000000000000612
Seidel D, et al. FungiScope(™)-global emerging fungal infection registry. Mycoses. 2017;60(8):508–16.
pubmed: 28730644 doi: 10.1111/myc.12631
Hoenigl M, et al. Global guidelines and initiatives from the European Confederation of Medical Mycology to improve patient care and research worldwide: new leadership is about working together. Mycoses. 2018;61(11):885–94.
pubmed: 30086186 doi: 10.1111/myc.12836
Egger M, et al. Predictors for Prolonged hospital stay solely to complete intravenous antifungal treatment in patients with candidemia: results from the ECMM candida III multinational european observational cohort study. Mycopathologia. 2023;188(6):983–94.
pubmed: 37566212 pmcid: 10687104 doi: 10.1007/s11046-023-00776-4
Arendrup MC, et al. European candidaemia is characterised by notable differential epidemiology and susceptibility pattern: Results from the ECMM Candida III study. J Infect. 2023;87(5):428–37.
pubmed: 37549695 doi: 10.1016/j.jinf.2023.08.001
Jensen RH, et al. Stepwise emergence of azole, echinocandin and amphotericin B multidrug resistance in vivo in Candida albicans orchestrated by multiple genetic alterations. J Antimicrob Chemother. 2015;70(9):2551–5.
pubmed: 26017038 pmcid: 4553713 doi: 10.1093/jac/dkv140
Rogers TR, et al. Molecular mechanisms of acquired antifungal drug resistance in principal fungal pathogens and EUCAST guidance for their laboratory detection and clinical implications. J Antimicrob Chemother. 2022;77(8):2053–73.
pubmed: 35703391 pmcid: 9333407 doi: 10.1093/jac/dkac161
Castanheira M, et al. Antifungal susceptibility patterns of a global collection of fungal isolates: results of the SENTRY Antifungal Surveillance Program (2013). Diagn Microbiol Infect Dis. 2016;85(2):200–4.
pubmed: 27061369 doi: 10.1016/j.diagmicrobio.2016.02.009
Pfaller MA, et al. Geographic variations in species distribution and echinocandin and azole antifungal resistance rates among Candida bloodstream infection isolates: report from the SENTRY Antimicrobial Surveillance Program (2008 to 2009). J Clin Microbiol. 2011;49(1):396–9.
pubmed: 21068282 doi: 10.1128/JCM.01398-10
Muskett H, et al. Risk factors for invasive fungal disease in critically ill adult patients: a systematic review. Crit Care. 2011;15(6):R287.
pubmed: 22126425 pmcid: 3388661 doi: 10.1186/cc10574
Keighley CL, et al. Risk factors for candidaemia: A prospective multi-centre case-control study. Mycoses. 2021;64(3):257–63.
pubmed: 33185290 doi: 10.1111/myc.13211
Arendrup MC, et al. Diagnostic issues, clinical characteristics, and outcomes for patients with fungemia. J Clin Microbiol. 2011;49(9):3300–8.
pubmed: 21715585 pmcid: 3165619 doi: 10.1128/JCM.00179-11
Ericsson J, et al. Candidaemia in Sweden: a nationwide prospective observational survey. Clin Microbiol Infect. 2013;19(4):E218–21.
pubmed: 23331511 doi: 10.1111/1469-0691.12111
Arendrup MC, et al. National surveillance of fungemia in Denmark (2004 to 2009). J Clin Microbiol. 2011;49(1):325–34.
pubmed: 20980569 doi: 10.1128/JCM.01811-10
Chong Y, et al. Fatal candidemia caused by azole-resistant Candida tropicalis in patients with hematological malignancies. J Infect Chemother. 2012;18(5):741–6.
pubmed: 22526385 doi: 10.1007/s10156-012-0412-9
Mazi PB, et al. Attributable mortality of candida bloodstream infections in the modern era: a propensity score analysis. Clin Infect Dis. 2022;75(6):1031–6.
pubmed: 34989802 pmcid: 10233239 doi: 10.1093/cid/ciac004
Salmanton-García J, Cornely OAC, Stemler J, Barac A, Steinmann J, Siváková A, Akalin EH, Arikan-Akdagli S, Loughlin L, Toscano C, Narayanan M, Rogers B, Willinger B, Akyol D, Roilides E, Lagrou K, Mikulska M, Denis B, Ponscarme D, Scharmann U, Azap A, Lockhart D, Bicanic T, Kron F, Erben N, Rautemaa-Richardson R, Goodman AL, Garcia-Vidal C, Lass-Flörl C, Gangneux J-P, Taramasso L, Ruiz M, Schick Y, Van Wijngaerden E, Milacek C, Giacobbe DR, Logan C, Rooney E, Gori A, Akova M, Bassetti M, Hoenigl M, Koehler P. Attributable mortality of candidemia—results from the ECMM Candida III multinational European Observational Cohort Study. 2024.
Salmanton-García J, et al. The current state of laboratory mycology and access to antifungal treatment in Europe: a European Confederation of Medical Mycology survey. Lancet Microbe. 2023;4(1):e47–56.
pubmed: 36463916 doi: 10.1016/S2666-5247(22)00261-0
Aerts R, et al. Circulatory Inflammatory Proteins as Early Diagnostic Biomarkers for Invasive Aspergillosis in Patients with Hematologic Malignancies-an Exploratory Study. Mycopathol 2024;189(2):24. https://doi.org/10.1007/s11046-024-00831-8
Hoenigl M, et al. Global guideline for the diagnosis and management of rare mould infections: an initiative of the European Confederation of Medical Mycology in cooperation with the International Society for Human and Animal Mycology and the American Society for Microbiology. Lancet Infect Dis. 2021;21:246–57.
doi: 10.1016/S1473-3099(20)30784-2
Hoenigl M, et al. Invasive candidiasis: investigational drugs in the clinical development pipeline and mechanisms of action. Expert Opin Investig Drugs. 2022;31(8):795–812.
pubmed: 35657026 pmcid: 9339492 doi: 10.1080/13543784.2022.2086120
Hoenigl M, et al. The antifungal pipeline: fosmanogepix, ibrexafungerp, olorofim, opelconazole, and rezafungin. Drugs. 2021;81(15):1703–29.
pubmed: 34626339 pmcid: 8501344 doi: 10.1007/s40265-021-01611-0
Duncan V, et al. Preliminary characterization of NP339, a novel polyarginine peptide with broad antifungal activity. Antimicrob Agents Chemother. 2021;65(8): e0234520.
pubmed: 34031048 doi: 10.1128/AAC.02345-20
Salmanton-García J, et al. The current state of laboratory mycology in Asia/Pacific: a survey from the European Confederation of Medical Mycology (ECMM) and International Society for Human and Animal Mycology (ISHAM). Int J Antimicrob Agents. 2023;61(3): 106718.
pubmed: 36640851 doi: 10.1016/j.ijantimicag.2023.106718

Auteurs

Stella Wolfgruber (S)

Division of Infectious Diseases, Department of Internal Medicine, Medical University of Graz, Auenbruggerplatz 15, 8036, Graz, Austria.
Translational Medical Mycology Research Unit, ECMM Excellence Center for Medical Mycology, Medical University of Graz, Graz, Austria.

Sarah Sedik (S)

Division of Infectious Diseases, Department of Internal Medicine, Medical University of Graz, Auenbruggerplatz 15, 8036, Graz, Austria.
Translational Medical Mycology Research Unit, ECMM Excellence Center for Medical Mycology, Medical University of Graz, Graz, Austria.

Lena Klingspor (L)

Division of Clinical Microbiology, Department of Laboratory Medicine, Karolinska Institutet, Stockholm, Sweden.

Annamaria Tortorano (A)

Dipartimento Scienze Biomediche per la Salute, Università degli Studi di Milano, Milan, Italy.

Neil A R Gow (NAR)

Medical Research Council Centre for Medical Mycology, Department of Biosciences, University of Exeter, Geoffrey Pope Building, Stocker Road, Exeter, UK.

Katrien Lagrou (K)

Laboratory of Clinical Microbiology, Department of Microbiology, Immunology and Transplantation, KU Leuven, Louvain, Belgium.
Department of Laboratory Medicine and National Reference Center for Mycosis, UZ Leuven, Leuven, Belgium.

Jean-Pierre Gangneux (JP)

Univ Rennes, CHU Rennes, Inserm, EHESP, Irset (Institut de recherche en santé, environnement et travail), UMR_S 1085, 35000, Rennes, France.
Laboratory of Mycology, Centre Hospitalier Universitaire de Rennes, Centre National de référence pour les mycoses et antifongiques - LA AspC, ECMM Excellence Center for Medical Mycology, Rennes, France.

Johan Maertens (J)

Department of Haematology and ECMM Excellence Center for Medical Mycology, University Hospitals Leuven, Campus Gasthuisberg, Leuven, Belgium.

Jacques F Meis (JF)

Department of Medical Microbiology, Excellence Center for Medical Mycology (ECMM), Center of Expertise in Mycology Radboudumc/CWZ, Nijmegen, The Netherlands.
University of Cologne, Faculty of Medicine and University Hospital Cologne, Cologne, Excellence Cluster on Cellular Stress Responses in Aging-Associated Diseases (CECAD), Cologne, Germany.

Cornelia Lass-Flörl (C)

Institute of Hygiene and Medical Microbiology Medical University of Innsbruck, Excellence Center for Medical Mycology (ECMM), Innsbruck, Austria.

Sevtap Arikan-Akdagli (S)

Department of Medical Microbiology, Hacettepe University Medical School, Ankara, Turkey.

Oliver A Cornely (OA)

University of Cologne, Faculty of Medicine and University Hospital Cologne, Department I of Internal Medicine, Center for Integrated Oncology Aachen Bonn Cologne Duesseldorf (CIO ABCD) and Excellence Center for Medical Mycology (ECMM), Cologne, Germany.
University of Cologne, Faculty of Medicine and University Hospital Cologne, Cologne, Excellence Cluster on Cellular Stress Responses in Aging-Associated Diseases (CECAD), Cologne, Germany.
German Centre for Infection Research (DZIF), Partner Site Bonn-Cologne, Cologne, Germany.
University of Cologne, Faculty of Medicine and University Hospital Cologne, Clinical Trials Centre Cologne (ZKS Köln), Cologne, Germany.

Martin Hoenigl (M)

Division of Infectious Diseases, Department of Internal Medicine, Medical University of Graz, Auenbruggerplatz 15, 8036, Graz, Austria. hoeniglmartin@gmail.com.
Translational Medical Mycology Research Unit, ECMM Excellence Center for Medical Mycology, Medical University of Graz, Graz, Austria. hoeniglmartin@gmail.com.
BioTechMed-Graz, Graz, Austria. hoeniglmartin@gmail.com.
ORCID: 0000-0002-1653-2824

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female

Evaluation of Low-Value Services Across Major Medicare Advantage Insurers and Traditional Medicare.

Ciara Duggan, Adam L Beckman, Ishani Ganguli et al.
1.00
Humans United States Aged Cross-Sectional Studies Medicare Part C

Effectiveness of Virtual Yoga for Chronic Low Back Pain: A Randomized Clinical Trial.

Hallie Tankha, Devyn Gaskins, Amanda Shallcross et al.
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH

questionsmedicales.fr › Eucaryotes › Animaux › Chordés › Vertébrés › Mammifères › Eutheria › Primates › Haplorhini › Catarrhini › Hominidae › Humains › Insights from Three Pan-European Multicentre...
questionsmedicales.fr › Infection › Infections bactériennes et mycoses › Mycoses › Infections fongiques invasives › Candidose invasive › Insights from Three Pan-European Multicentre...
questionsmedicales.fr › Actions chimiques et utilisations › Actions pharmacologiques › Utilisations thérapeutiques › Anti-infectieux › Antifongiques › Insights from Three Pan-European Multicentre...
questionsmedicales.fr › Eucaryotes › Champignons › Levures › Candida › Insights from Three Pan-European Multicentre...
questionsmedicales.fr › Phénomènes physiologiques › Phénomènes pharmacologiques et toxicologiques › Phénomènes pharmacologiques › Résistance aux substances › Résistance microbienne aux médicaments › Résistance des champignons aux médicaments › Insights from Three Pan-European Multicentre...
questionsmedicales.fr › Régions géographiques › Europe › Insights from Three Pan-European Multicentre...
questionsmedicales.fr › États, signes et symptômes pathologiques › Processus pathologiques › Inflammation › Sepsie › Fongémie › Candidémie › Insights from Three Pan-European Multicentre...
questionsmedicales.fr › Environnement et santé publique › Santé publique › Méthodes épidémiologiques › Caractéristiques des études épidémiologiques › Études multicentriques comme sujet › Insights from Three Pan-European Multicentre...